Contributing factors in the prolonged effect of botulinum toxin




Botulinum enzyme; Botox; Prolonged effect; Contributing factors.


Botulinum enzyme, more commonly referred to as botulinum toxin or Botox (BT), is a neurotoxin derived from Gram-positive bacteria. The effectiveness of botulinum toxin can vary from person to person and depends on the dose administered, the application technique and the indication for which it is being used. With this in mind, this study aims to investigate the factors contributing to the prolonged effect of botulinum toxin, by means of an integrative review. This is an integrative bibliographic review, which aims to explore and synthesize an analysis of the use of botulinum enzyme and the contributing effects of prolonged action in the aesthetic area, by searching for the most representative published studies on the subject in question. After inclusion and exclusion criteria, 15 manuscripts were selected for presentation and discussion of the results, as they responded to the objectives. Most of the samples came from Medline/PubMed with 67% of the searches, followed by Scielo with 27%, 65% of which used clinical trials with a qualitative approach. Clinical studies have shown that botulinum toxin type A can be effective in reducing the frequency and intensity of migraine attacks in patients with chronic migraine. However, not all patients respond in the same way, and the benefits may vary. In addition, it is important to discuss potential adverse reactions and specific considerations with a healthcare professional before opting for this treatment. However, the application of botulinum toxin can bring with it some side effects resulting from the injection or the product.


Ababneh, O. H., Cetinkaya, A., & Kulwin, D. R. (2014). Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 42(3),254-61.

Bratz, P. D. E., & Mallet, E. K. V. (2015). Toxina Botulínica Tipo A: Abordagens em Saúde. Revista Saúde Integrada. 8(15-16),1-12.

Campanati, A., Martina, E., Giuliodori, K., et al. (2017). Toxina botulínica fora do rótulo na dermatologia: uma revisão. Disord. 3(1),39-56.

Carr, W. , Jain, N., & Sublett, J. W. (2021). Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Adv Ther. 38(10),5046-5064.

Colhado, O. C. G., Boeing, M., & Ortega, L. B. (2009). Toxina Botulínica no tratamento da dor. Revista Brasileira de Anestesiologia. 59(3), 366-381.

Costa, A., Pereira, E. S. P., Santos, F. B. C., & Arruda, L. H. F. (2012). Comparative clinical study of the diffusion characteristics of 5 different botulinum toxins used in clinical approach, in 5 gradually increasing doses. Aesthetic Dermatology. 66(4),25.

Czyz, C. N., Burns, J. A., Petrie, T. P., Watkins, J. R., Cahill, K. V., & Foster, J. A. (2013). Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome. American Journal of Ophthalmology. 156(1),173-177.

Dashtipour, K., & Pedouim, F. (2016). Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile. Semin Neurol. 36(1),29-33.

Delpachitra, S. N., Sklavos, A. W., & Dastaran, M. (2018). Clinical uses of botulinum toxin A in smile aesthetic modification. Br Dent J. 225(6),502-6.

Dorizas, A., Krueger, N., & Sadick, N. S. (2014). Aesthetic uses of the botulinum toxin. Dermatol Clin. 32(1),23-36.

Duruel, O., Ataman, D. E. T., Berker, E., et al. (2019). Treatment of various types of gummy smile with botulinum toxin-A. J Craniofac Surg. 30(3),876-8.

Gart, M. S., & Gutowski, K. A. (2016). Overview of Botulinum Toxins for Aesthetic Uses. Clin Plast Surg. 43(3),459-71.

Gazerani, P. (2018). Antipruritic Effects of Botulinum Neurotoxins. Toxins (Basel). 10(4),143.

Gazerani, P. (2020). How Does Botulinum Toxin Inhibit Itch? Toxins. 14(10),701.

Gharib, K., Mostafa, A., & Elsaved, A. (2020). Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus. J Clin Aesthet Dermatol. 13(12),12-17.

Gimenez, R. P. (2006). Análise retrospectiva das alterações de dinâmica facial após aplicações seriadas de toxina botulínica tipo A. 131 f. Dissertação (Mestrado em Ciências) – Faculdade de Medicina, Universidade de São Paulo, São Paulo.

Guo, B. L., Zheng, C. X., Sui, B. D., Li, Y. Q., Wang, Y. Y., & Yang, Y. L. (2013). A closer look to botulinum neurotoxin type A- induced analgesia. Toxicon. 71(2),134-139.

Helmi, Z. R. (2022). Comparative Study of 150 vs. 200 Units of Botulinum Toxin as Treatment for Vaginismus Estudo comparativo de 150 vs. 200 unidades de toxina botulínica como tratamento para vaginismo. Rev Bras Ginecol Obstet. 44(9),854-865.

Herd, C. P., Tomlinson, C. L., Rick, C., et al. (2018). Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews. 6(6),116-126.

Koshy, J. C., Sharabi, S. E., Feldman, E. M., Hollier Jr, L. H., Patrinely, J. R., & Soparkar, C. N. S. (2012). Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol. 11(4),507-12.

Kumar, Raj. (2018). Therapeutic use of botulinum toxin in pain treatment. Neuronal Signal. 2(3), NS20180058.

Leumann, A., Longino, D., Fortuna, R., Leonard, T., Vaz, M. A., Hart, D. A., & Herzog, W. (2012). Altered cell metabolism in tissues of the knee joint in a rabbit model of Botulinum toxin A-induced quadriceps muscle weakness. Scand J Med Sci Sports. 22(6), 776-82.

Nattkemper, L. A., Does, A. V., Stull, C. M., Lavery, M. J., Rodriguez, R. V., & McGregory, M. (2023). Prolonged Antipruritic Effect of Botulinum Toxin Type A on Cowhage-induced Itch: A Randomized, Single-blind, Placebo-controlled Trial. Acta Derm Venereol. 16(103), adv6581.

Nattkemper, L. A., Vander Does, A., Stull, C. M., et al. (2023). Prolonged Antipruritic Effect of Botulinum Toxin Type A on Cowhage-induced Itch: A Randomized, Single-blind, Placebo-controlled Trial. Acta Dermato-Venereologica, 103(5),6581.

Nestor, M., Ablon, G., & Pickett, A. (2017). Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration. Aesthet Surg J. 37(Suppl 1), S20-S31.

Nestor, M., Arnold, D., & Fischer, D. (2020). The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II. J Cosmet Dermatol. 19(11), 2785-2804.

Pak, A. T., Üstün, İ., & Sengul, Y. (2021). Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de Neuro-Psiquiatria. 79(10),886-890.

Pereira A. S. et al. (2018). Metodologia da pesquisa científica. UFSM.

Reis, G. M. D., Guerra, A. C. S., & Ferreira, J. P. A. (2011). Estudo de pacientes com hiperidrose, tratados com toxina botulínica: análise retrospectiva de 10 anos. Rev. Bras. Cir. Plást. 26(4),582-90.

Rossetto, O., Pirazzini, M., & Montecucco, C. (2014). Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature Reviews Microbiology. 12(8),535-549.

Sätilä, H. (2020). Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections? Toxins. 12(7), 440.

Silva, M. L. et al. (2021). Utilização da toxina botulínica tipo A para fins terapêuticos. Research, Society and Development. 10(14),e535101422385-e535101422385.

Sousa, L. M. M., Vieira, C. M. A. M., Severino, S. S. P., et al. (2017). A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem. 5(1),17-26.

Stefane, T., Napoleão, A. A., Sousa, F. A. E. F., & Hortense, P. (2012). Influência de tratamentos para enxaqueca na qualidade de vida: revisão integrativa de literatura. Revista Brasileira de Enfermagem. 65(2),353-360.

Tugcu, B., Ersan, B. A., & Özkan, S. B. (2024). Botulinum toxin A for the treatment of strabismus in children with neurological impairment. Arq Bras Oftalmol. 87(4), e2021-0401.

Viggiani, D. F. E. B., & Pereira, D. K. S. (2023). Efeito prolongado da toxina botulínica associada à suplementação com zinco e fitase. Arquivos De Ciências Da Saúde Da UNIPAR. 27(7),3733-3745.

Yiannakopoulou, E. (2015). Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 95(1-2),65-9.

Youssef, A. R., Seerattan, D. L., Leonard, R. T., & Herzog, W. (2009). Muscle weakness causes joint degeneration in rabbits. Osteoarthritis Cartilage. 17(9),1228-35.



How to Cite

LACERDA, V. R. L. .; FERREIRA, P. de O. A. .; SILVA, M. V. B. .; SOUSA, M. A. D. G. dos S. .; LIMA, L. C. S. .; DINIZ, I. G.; GUIMARÃES, M. C. M. . Contributing factors in the prolonged effect of botulinum toxin. Research, Society and Development, [S. l.], v. 13, n. 1, p. e1113144675, 2024. DOI: 10.33448/rsd-v13i1.44675. Disponível em: Acesso em: 20 may. 2024.



Health Sciences